{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-033021","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.351040+00:00","generated_at":"2026-06-13T08:20:17.256863+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Revelation Biosciences stockholders elect directors, approve equity plan increase, ratify auditor","bullets":["Quorum of 2,309,314 shares (>1/3 of 5,773,983 outstanding) present or proxy.","Directors Jennifer Carver (1,281,109 for) and Curt LaBelle (1,280,290 for) elected to Class A.","Approved amendment to 2021 Equity Incentive Plan: shares reserved increased from 68,288 to 648,678 (1,124,336 for).","Ratified Baker Tilly US, LLP as auditor for fiscal year ending Dec 31, 2023 (1,981,630 for)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-033021","json":"https://secwatch.observer/filing/0000950170-23-033021.json","markdown":"https://secwatch.observer/filing/0000950170-23-033021.md","text":"https://secwatch.observer/filing/0000950170-23-033021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023033021/0000950170-23-033021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023033021/revb-20230714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:20:17.256863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01fbb35b92edb57c5c969e22da3d1b527751d4c4","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Ratification of the Auditor at the 2023-12-31 meeting.","evidence_excerpt":"Stockholders approved Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2023, based on the votes listed below: For Against Abstain 1,981,630 26,027 301,657","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023033021/0000950170-23-033021-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"75b237743255f9f1b76f3bbae1f7677d5726f497","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Approval of to increase he number of shares reserved under the Company’s 2021 Equity Incentive Plan.","evidence_excerpt":"Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the Plan from 68,288 to 648,678, based on the votes listed below: For Against Abstain 1,124,336 224,337 15,961","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023033021/0000950170-23-033021-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"c9158e7cbd02d0078946c9717f30ab5b7e7a7109","claim":"REVELATION BIOSCIENCES, INC. shareholders approved Election of Directors.","evidence_excerpt":"Stockholders approved to elect the two nominees for Class A director named herein to serve until the 2026 Annual Meeting or their successors are duly elected and qualified., based on the votes listed below: Director Nominee For Against Abstain Jennifer Carver 1,281,109 68,257 15,268 Curt LaBelle 1,280,290 66,949 17,395","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023033021/0000950170-23-033021-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}